Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biliary Atresia | 4 | 2025 | 224 | 1.700 |
Why?
|
| Portoenterostomy, Hepatic | 4 | 2025 | 62 | 1.600 |
Why?
|
| Bile Acids and Salts | 3 | 2025 | 260 | 0.930 |
Why?
|
| Liver Transplantation | 5 | 2025 | 1136 | 0.850 |
Why?
|
| Infant Formula | 1 | 2024 | 105 | 0.810 |
Why?
|
| Child Development | 1 | 2025 | 267 | 0.730 |
Why?
|
| Milk, Human | 1 | 2024 | 318 | 0.700 |
Why?
|
| Bevacizumab | 1 | 2020 | 59 | 0.620 |
Why?
|
| Macular Edema | 1 | 2020 | 27 | 0.620 |
Why?
|
| Gastrointestinal Microbiome | 2 | 2025 | 830 | 0.600 |
Why?
|
| Diabetic Retinopathy | 1 | 2020 | 81 | 0.580 |
Why?
|
| Microbiota | 1 | 2020 | 438 | 0.430 |
Why?
|
| Cholangitis, Sclerosing | 2 | 2024 | 75 | 0.360 |
Why?
|
| End Stage Liver Disease | 1 | 2014 | 193 | 0.360 |
Why?
|
| Decision Support Techniques | 1 | 2014 | 292 | 0.340 |
Why?
|
| Cholestasis | 2 | 2022 | 170 | 0.320 |
Why?
|
| Infant | 9 | 2025 | 13261 | 0.320 |
Why?
|
| Brain Diseases, Metabolic, Inborn | 2 | 2021 | 26 | 0.310 |
Why?
|
| Purpura | 2 | 2021 | 25 | 0.310 |
Why?
|
| Graft Rejection | 2 | 2025 | 558 | 0.300 |
Why?
|
| Clostridium Infections | 2 | 2021 | 248 | 0.240 |
Why?
|
| Treatment Outcome | 7 | 2025 | 12836 | 0.220 |
Why?
|
| Acetylcysteine | 1 | 2025 | 79 | 0.210 |
Why?
|
| Sirolimus | 1 | 2025 | 231 | 0.200 |
Why?
|
| Inflammatory Bowel Diseases | 2 | 2024 | 323 | 0.180 |
Why?
|
| Liver | 3 | 2025 | 1788 | 0.180 |
Why?
|
| Vancomycin | 1 | 2024 | 223 | 0.180 |
Why?
|
| Alagille Syndrome | 1 | 2022 | 54 | 0.180 |
Why?
|
| Disease Resistance | 1 | 2021 | 23 | 0.180 |
Why?
|
| Cholestasis, Intrahepatic | 1 | 2022 | 59 | 0.180 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 655 | 0.170 |
Why?
|
| Hypertension, Portal | 1 | 2021 | 78 | 0.160 |
Why?
|
| Bile | 1 | 2020 | 44 | 0.160 |
Why?
|
| Intravitreal Injections | 1 | 2020 | 41 | 0.160 |
Why?
|
| France | 1 | 2020 | 90 | 0.160 |
Why?
|
| Elasticity Imaging Techniques | 1 | 2022 | 157 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2020 | 112 | 0.150 |
Why?
|
| Humans | 17 | 2025 | 130056 | 0.150 |
Why?
|
| Liver Diseases | 1 | 2022 | 379 | 0.140 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 320 | 0.140 |
Why?
|
| Organoids | 1 | 2021 | 298 | 0.140 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2020 | 331 | 0.140 |
Why?
|
| Intestines | 1 | 2021 | 587 | 0.130 |
Why?
|
| Child | 8 | 2025 | 26158 | 0.130 |
Why?
|
| Child, Preschool | 5 | 2025 | 14991 | 0.130 |
Why?
|
| Registries | 2 | 2021 | 1607 | 0.120 |
Why?
|
| Stem Cells | 1 | 2021 | 704 | 0.120 |
Why?
|
| Male | 9 | 2025 | 64359 | 0.110 |
Why?
|
| Biomarkers | 3 | 2022 | 3355 | 0.110 |
Why?
|
| Female | 9 | 2025 | 70231 | 0.110 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 774 | 0.100 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1908 | 0.100 |
Why?
|
| Stroke | 1 | 2021 | 1056 | 0.100 |
Why?
|
| Age Factors | 2 | 2021 | 2822 | 0.090 |
Why?
|
| Endoscopy, Digestive System | 1 | 2013 | 151 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2014 | 208 | 0.090 |
Why?
|
| Waiting Lists | 1 | 2014 | 250 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2021 | 3744 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2563 | 0.090 |
Why?
|
| Infant, Newborn | 1 | 2024 | 8547 | 0.090 |
Why?
|
| Cytokines | 1 | 2017 | 1336 | 0.090 |
Why?
|
| Abdominal Pain | 1 | 2013 | 316 | 0.080 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 5160 | 0.080 |
Why?
|
| Tissue Donors | 1 | 2014 | 506 | 0.080 |
Why?
|
| Budesonide | 1 | 2009 | 18 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2013 | 336 | 0.080 |
Why?
|
| Interleukin-8 | 2 | 2022 | 200 | 0.070 |
Why?
|
| Retrospective Studies | 3 | 2025 | 17544 | 0.070 |
Why?
|
| Brain | 1 | 2021 | 3146 | 0.070 |
Why?
|
| Adolescent | 6 | 2025 | 20788 | 0.070 |
Why?
|
| Eosinophils | 1 | 2009 | 119 | 0.070 |
Why?
|
| Sinusitis | 1 | 2009 | 118 | 0.070 |
Why?
|
| Eosinophilia | 1 | 2009 | 110 | 0.070 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2009 | 298 | 0.060 |
Why?
|
| Risk Factors | 2 | 2021 | 10944 | 0.050 |
Why?
|
| Administration, Intravenous | 1 | 2025 | 170 | 0.050 |
Why?
|
| Remission Induction | 1 | 2024 | 306 | 0.050 |
Why?
|
| Matrix Metalloproteinase 7 | 1 | 2022 | 25 | 0.050 |
Why?
|
| Endoglin | 1 | 2022 | 30 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2024 | 3024 | 0.050 |
Why?
|
| Butyrates | 1 | 2022 | 39 | 0.050 |
Why?
|
| Pruritus | 1 | 2022 | 51 | 0.050 |
Why?
|
| Aged | 1 | 2020 | 20823 | 0.040 |
Why?
|
| Administration, Oral | 1 | 2024 | 706 | 0.040 |
Why?
|
| Benzodiazepines | 1 | 2022 | 105 | 0.040 |
Why?
|
| gamma-Glutamyltransferase | 1 | 2021 | 49 | 0.040 |
Why?
|
| Enterohepatic Circulation | 1 | 2021 | 10 | 0.040 |
Why?
|
| Aspartate Aminotransferases | 1 | 2021 | 80 | 0.040 |
Why?
|
| Time | 1 | 2021 | 92 | 0.040 |
Why?
|
| Alanine Transaminase | 1 | 2021 | 154 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2021 | 242 | 0.040 |
Why?
|
| Internationality | 1 | 2021 | 127 | 0.040 |
Why?
|
| Middle Aged | 1 | 2020 | 28310 | 0.040 |
Why?
|
| Graft Survival | 1 | 2021 | 466 | 0.040 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2019 | 6 | 0.040 |
Why?
|
| Glucocorticoids | 1 | 2021 | 347 | 0.040 |
Why?
|
| Stomach | 1 | 2021 | 270 | 0.040 |
Why?
|
| Consanguinity | 1 | 2019 | 115 | 0.040 |
Why?
|
| Recurrence | 1 | 2021 | 1475 | 0.030 |
Why?
|
| Interleukin-5 | 1 | 2017 | 49 | 0.030 |
Why?
|
| Glucosyltransferases | 1 | 2017 | 44 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2019 | 283 | 0.030 |
Why?
|
| Interleukin-17 | 1 | 2017 | 125 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2886 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2021 | 1872 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 410 | 0.030 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 902 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2017 | 544 | 0.030 |
Why?
|
| Disease Progression | 1 | 2021 | 2193 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2024 | 5037 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3810 | 0.020 |
Why?
|
| Time Factors | 1 | 2021 | 6173 | 0.020 |
Why?
|
| Administration, Inhalation | 1 | 2009 | 192 | 0.020 |
Why?
|
| Phenotype | 1 | 2019 | 4461 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4847 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2009 | 1440 | 0.010 |
Why?
|
| Mutation | 1 | 2019 | 6068 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2009 | 1241 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 18158 | 0.010 |
Why?
|
| Helicobacter pylori | 1 | 2013 | 1368 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 6396 | 0.010 |
Why?
|
| Animals | 1 | 2021 | 33678 | 0.010 |
Why?
|
| United States | 1 | 2013 | 11879 | 0.010 |
Why?
|